Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 5-year disease-free and overall survival data

被引：0
|
作者：
Vriens, B. [1 ]
Aarts, M. [1 ]
Van Gastel, S. [2 ]
Van den Berkmortel, F. [3 ]
Smilde, T. [4 ]
Van Warmerdam, L. [5 ]
De Boer, M. [1 ]
Van Spronsen, D. J. [6 ]
Peer, P. [7 ]
Tjan-Heijnen, V. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Med Oncol, NL-6200 MD Maastricht, Netherlands
[2] Comprehens Canc Ctr Netherlands, Canc Registry, Nijmegen, Netherlands
[3] Zuyderland Hosp, Med Oncol, Heerlen, Netherlands
[4] Jeroen Bosch Hosp, Med Oncol, Shertogenbosch, Netherlands
[5] Catharina Hosp, Med Oncol, Eindhoven, Netherlands
[6] Canisius Wilhelmina Hosp, Med Oncol, Nijmegen, Netherlands
[7] Radboud Inst Hlth Sci, Biostat, Nijmegen, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [21] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [22] Surviving cancer: A comparison of 5-year disease-free breast cancer survivors with healthy women
    Helgeson, VS
    Tomich, PL
    PSYCHO-ONCOLOGY, 2005, 14 (04) : 307 - 317
  • [23] A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics
    Shen, K.
    Tang, G.
    Kim, C.
    Pogue-Geile, K.
    Anderson, S. J.
    Constantino, J. P.
    Bear, H. D.
    Song, N.
    Tian, C.
    Gabrin, M. J.
    Zhang, Y.
    Geyer, C. E., Jr.
    Wolmark, N.
    CANCER RESEARCH, 2011, 71
  • [24] Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
    Walker, Leslie G.
    Eremin, Jennifer M.
    Aloysius, Mark M.
    Vassanasiri, Wichai
    Walker, Mary B.
    El-Sheemy, Mohamed
    Cowley, Ged
    Beer, Jeanette
    Samphao, Srila
    Wiseman, Janice
    Jibril, Jibril A.
    Valerio, David
    Clarke, David J.
    Kamal, Mujahid
    Thorpe, Gerald W.
    Baria, Karin
    Eremin, Oleg
    BMC CANCER, 2011, 11
  • [25] Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
    Earl, H. M.
    Hiller, L.
    Dunn, J. A.
    Blenkinsop, C.
    Grybowicz, L.
    Vallier, A. -L.
    Gounaris, I.
    Abraham, J. E.
    Hughes-Davies, L.
    McAdam, K.
    Chan, S.
    Ahmad, R.
    Hickish, T.
    Rea, D.
    Caldas, C.
    Bartlett, J. M. S.
    Cameron, D. A.
    Provenzano, E.
    Thomas, J.
    Hayward, R. L.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1817 - 1824
  • [26] Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
    Leslie G Walker
    Jennifer M Eremin
    Mark M Aloysius
    Wichai Vassanasiri
    Mary B Walker
    Mohamed El-Sheemy
    Ged Cowley
    Jeanette Beer
    Srila Samphao
    Janice Wiseman
    Jibril A Jibril
    David Valerio
    David J Clarke
    Mujahid Kamal
    Gerald W Thorpe
    Karin Baria
    Oleg Eremin
    BMC Cancer, 11
  • [27] A gene expression signature in HER2+breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
    Barron-Gallardo, Carlos A.
    Garcia-Chagollan, Mariel
    Moran-Mendoza, Andres J.
    Delgadillo-Cristerna, Raul
    Martinez-Silva, Maria G.
    Villasenor-Garcia, Maria M.
    Aguilar-Lemarroy, Adriana
    Jave-Suarez, Luis F.
    FRONTIERS IN GENETICS, 2022, 13
  • [28] Immunohistochemical subtype and its relationship with 5-year overall survival in breast cancer patients
    Aldaz-Roldan, Pablo
    Pardo-Vasquez, Diego F.
    Chamba-Morales, Geanella N.
    Aguirre-Reyes, Daniel F.
    Castillo-Calvas, Johana M.
    Noblecilla-Arevalo, Gabriela
    ECANCERMEDICALSCIENCE, 2023, 17
  • [29] Overall 5-year survival of breast cancer patients: The real-life experience from linked data
    Shafiq, Jesmin
    Merie, Roya
    Soon, Patsy S.
    Delaney, Geoff
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 83 - 84
  • [30] Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.
    Sonpavde, G.
    Khan, M. M.
    Lerner, S. P.
    Svatek, R. S.
    Skinner, E. C.
    Karakiewicz, P. I.
    Kassouf, W.
    Dinney, C. P.
    Fradet, Y.
    Shariat, S. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345